OncoMatch/Clinical Trials/NCT04700527
The Effects of SCFA Supplementation in Subjects Receiving Abdominopelvic RT: A Randomized Controlled Study
Is NCT04700527 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Short Chain Fatty Acid and Tapioca Flour for toxicity.
Treatment: Short Chain Fatty Acid · Tapioca Flour — The purpose of this study is to assess and compare GI toxicity from RT between subjects who receive therapeutic SCFA and those who receive placebo, in hopes of identifying a safe, low-cost therapeutic to reduce GI toxicity from therapeutic or environmental radiation.
Check if I qualifyExtracted eligibility criteria
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: abdominopelvic radiation therapy
Lab requirements
Kidney function
Creatinine clearance < 50 mL/min [excluded]
Cardiac function
Congestive heart failure [excluded]
Creatinine clearance < 50 mL/min; Congestive heart failure [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Flora Danquah · Chapel Hill, North Carolina
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify